title: [Analysis of concurrent chemoradiotherapy in patients with stage III non-small cell lung cancer after two cycles of induction chemotherapy].
abstract: BACKGROUND
  Recently chemoradiotherapy becomes a standard treatment of un-resectable advanced non-small cell lung cancer (NSCLC) instead of radiotherapy alone. This study is to evaluate the clinical effect and toxicities of concurrent chemoradiotherapy in patients with stage III NSCLC after 2 cycles of induction chemotherapy with cisplatin-based regimens.
  
  
  METHODS
  Ninety-two patients with stage III NSCLC were divided randomly into two groups: forty-seven patients received concurrent chemoradiotherapy (chemoradiotherapy group), the other 45 patients received only radiotherapy (radiotherapy group). For both groups, the same radiation technic was given with the conventional fraction. The total dose was 60-65Gy/30-33Fr/6-6.5Wk. For the chemoradiotherapy group, the patients were also given with concurrent chemotherapy (navelbine 15-18mg/m² on the 1st and 8th day, cisplatin 60mg/m² on the 1st day).
  
  
  RESULTS
  The response rate in the chemoradiotherapy group was similar to that in the radiotherapy group (59.6% vs 51.5%, P > 0.05), but the complete response rate in the chemoradiotherapy group was significantly higher than that in the radiotherapy group (14.9% vs 6.7%, P < 0.05). The 1- and 2-year survival rates in the chemoradiotherapy group were similar to those in the radiotherapy group (65.9% and 42.5% vs 53.3% and 33.3%, P > 0.05). The 1- and 2-year local control rates in the chemoradiotherapy group were significantly higher than those in the radiotherapy group (63.8% and 53.2% vs 51.1% and 44.4%, P < 0.05). The incidences of grade III-IV radiation esophagitis and leukopenia in the chemoradiotherapy group were significantly higher than those in the radiotherapy group (21.2% and 12.7% vs 4.4% and 0, P < 0.01).
  
  
  CONCLUSIONS
  Concurrent chemoradiotherapy has the potential of improving the survival rate of stage III NSCLC, it can also increase the acute toxic effect, but all patients can tolerate this treatment regimen.
authors.affiliation: Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai 200030, P.R.China.
authors.forename: Changxing
authors.initials: C
authors.lastname: Lv
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
authors.forename: Jiaming
authors.initials: J
authors.lastname: Wang
authors.forename: Changlu
authors.initials: C
authors.lastname: Wang
authors.forename: Jingdong
authors.initials: J
authors.lastname: Guo
authors.forename: Fanghua
authors.initials: F
authors.lastname: Pan
authors.forename: Jie
authors.initials: J
authors.lastname: Jiang